Asset
Cyclophosphamide
Cartesian Therapeutics Inc. Common Stock
Revenue
No revenue reported in loaded filings.
Clinical trials (2)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT03448978 | phase1 | terminated | 2018-03-08 | 2021-04-19 | Cartesian Therapeutics | Autologous CD8+ T-cells Expressing an Anti-BCMA CAR in Patients With Myeloma |
| NCT03994705 | phase1 | terminated | 2019-08-01 | 2021-05-27 | Cartesian Therapeutics | Descartes-11 in Patients With Relapsed/Refractory Multiple Myeloma |
FDA applications (0)
This company has no applications containing this asset.